Management of Recurrent Retroperitoneal Sarcoma (RPS) in the adult

• Verfasst von: Åhlén, Jan [VerfasserIn]
• Verfasst von: Henzler, Thomas [VerfasserIn]
• Verfasst von: Hohenberger, Peter [VerfasserIn]
• Verfasst von: Jakob, Jens [VerfasserIn]
• Titel: Management of Recurrent Retroperitoneal Sarcoma (RPS) in the adult
• Titelzusatz: a consensus approach from the trans-atlantic RPS working group
• Verf.angabe: Trans-Atlantic RPS Working Group*
• E-Jahr: 2016
• Jahr: 1 August 2016
• Umfang: 10 S.
• Fussnoten: Gesehen am 26.06.2019 ; Trans-Atlantic RPS Working Group: Jan Ahlen, Department of Surgery, Karolinska Hospital, Stockholm, Sweden, ..., Thomas Henzler, Institute of Clinical Radiology and Nuclear Medicine, University Medical Center Mannheim, Heidelberg University, Mannheim, Germany, Peter Hohenberger, Department of Surgical Oncology and Thoracic Surgery, Mannheim, Germany, Antoine Italiano, Department of Cancer Medicine, Institute Bergonie, Bordeaux, France, Jens Jakob, Department of Surgical Oncology and Thoracic Surgery, Mannheim, Germany und 25 weitere
• Titel Quelle: Enthalten in: Annals of surgical oncology
• Ort Quelle: Berlin [u.a.] : Springer, 1994
• Jahr Quelle: 2016
• Band/Heft Quelle: 23(2016), 11, Seite 3531-3540
• ISSN Quelle: 1534-4681
• DOI: doi:10.1245/s10434-016-5336-7
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Clear Cell Sarcoma
• Sach-SW: Malignant Peripheral Nerve Sheath Tumor
• Sach-SW: Netherlands Cancer Institute
• Sach-SW: Sarcoma
• Sach-SW: Synovial Sarcoma
• K10plus-PPN: 1667968904

Abstract

IntroductionRetroperitoneal soft tissue sarcomas (RPS) are rare tumors. Surgery is the mainstay of curative therapy, but local recurrence is common. No recommendations concerning the best management of recurring disease have been developed so far. Although every effort should be made to optimize the initial approach, recommendations to treat recurring RPS will be helpful to maximize disease control at recurrence.MethodsAn RPS transatlantic working group was established in 2013. The goals of the group were to share institutional experiences, build large multi-institutional case series, and develop consensus documents on the approach to this difficult disease. The outcome of this document applies to recurrent RPS that is nonvisceral in origin. Included are sarcomas of major veins, undifferentiated pleomorphic sarcoma of psoas, ureteric leiomyosarcoma (LMS). Excluded are desmoids-type fibromatosis, angiomyolipoma, gastrointestinal stromal tumors, sarcomas arising from the gut or its mesentery, uterine LMS, prostatic sarcoma, paratesticular/spermatic cord sarcoma, Ewing sarcoma, alveolar/embryonal rhabdomyosarcoma, sarcoma arising from teratoma, carcinosarcoma, sarcomatoid carcinoma, clear cell sarcoma, radiation-induced sarcoma, paraganglioma, and malignant pheochromocytoma.ResultsRecurrent RPS management was evaluated from diagnosis to follow-up. It is a rare and complex malignancy that is best managed by an experienced multidisciplinary team in a specialized referral center. The best chance of cure is at the time of primary presentation, but some patients may experience prolonged disease control also at recurrence, when the approach is optimized and follows the recommendations contained herein.ConclusionsInternational collaboration is critical for adding to the present knowledge. A transatlantic prospective registry has been established.